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Abstract
Objectives:To compare the clinical benefits of granulocyte-colony stimulating factor (GCSF) or granulocyte macrophage-colony stimulating factor (GM-CSF) plus standard
supportive care to supportive care alone among cancer patients with febrile neutropenia.
Methods:Clinical data were collected retrospectively from 148 consecutive cancer patients
with neutropenia and fever. Patients had hematologic (i.e., acute leukemias or
lymphoproliferative disorders) or non-hematologic malignancies (i.e., solid tumors
including carcinoma of breast, lung, or colon). Clinical variables analyzed included: age
and sex; underlying malignancies; chemotherapy regimens; symptoms at time of
presentation; duration of fever prior to study enrollment; days from chemotherapy until
administration of GM-CSF or G-CSF; number of previous neutropenic episodes; duration
of fever and day of defervescence; absolute neutrophil count on day of defervescence;
duration of neutropenia; number and types of antibiotics used; day amphotericin B begun;
number of culture-documented infective episodes involving bloodstream, lung, pleura,
urinary tract, gastrointestinal tract, intravenous cannulae, or skin; types of antimicrobial
isolates; cost of cytokine therapy; length of hospital stay and clinical outcome.
Results:The use of myeloid growth factors increased the number of circulating peripheral
white blood cells, but no significant effect was noted in terms of duration of neutropenia or
fever, number of culture-proven infections (except pneumonia; p < 0.04), length of hospital
stay, or survival.
Conclusion:In areas with limited health care resources, expensive treatment with GM-CSF
or G-CSF should be reserved for patients with complicated febrile neutropenia where the
expected risk of infection is high and the documented infections that are refractory to
antibiotic duration of neutropenia is prolonged, or those with treatment (JPMA 52: 206,
2002).
Introduction
The precise role of hematopoietic growth factors in the management of patients with
neutropenia and fever remains uncertain. Granulocyte-colony stimulating factor (G-CSF or
filgrastin) and granulocyte macrophage-colony stimulating factor (GM-CSF or
sargramostim) have become popular modalities used in the management of patients with
cancer chemotherapy-induced neutropenia. A number of clinical studies have demonstrated

the potential ability of these factors to decrease the duration of cytotoxic-induced
neutropenia, number of febrile days and reduce hospital stay1-5. However, not all
investigators have demonstrated substantial benefit from the use of myeloid colony
stimulating factors6-8 and their relatively high cost must be seriously considered when
contemplating the use of G-CSF and GM-CSF in countries like Pakistan with limited health
care resources. In order to determine the appropriateness and cost-effectiveness of these
cytokines in local setting, we conducted a comparative study of GM-CSF or G-CSF plus
standard supportive care versus supportive care alone in chemotherapy-induced
neutropenic fever and evaluated several targeted outcome measures.
Patients and Methods
During the period January 1997 through March 1998, clinical data were collected
retrospectively from consecutive patients seen on the oncology service with neutropenia
(defined as an absolute neutrophil count < 500/cu mm or between 500-1,000/cu mm but
rapidly dropping) and fever (defined as a temperature elevation above 38.3°C. Patients had
hematologic (i.e., acute leukemias or lymphoproliferative disorders) or nonhematologic
malignancies (i.e., solid tumors including carcinoma of breast, lung, colon). Various
chemotherapy regimens are shown in Table 1.

Conventional supportive care involved initiation of empiric two-drug antibacterial therapy
with the development of fever (generally, piperacillin/tazobactam plus amikacin;
vancomycin was added if patients had evidence of catheter-related infection such as signs
of inflammation around a central or peripheral catheter, or tenderness overlying a
subcutaneous catheter port). Empiric antifungal treatment with iv amphotericin B was
begun if patients remained febrile for more than five days. Due to economic considerations,
growth factors were begun at the time of development of fever rather than at the onset of
neutropenia. Growth factors were administered in the following doses: G-CSF ugfkg] (n =
27) or GM-CSF ug/m2} (n = 40). Therapy with growth factors was continued for a mean of

3.93 days (range 1-9 days).
Clinical variables analyzed included age and sex; AD = cytosine arabinoside 100 mg/rn2 x
7d plus daunorubicin 45 mg/rn2 x 3d; ADE = cytosine arabinoside 100 mg/rn2 x 7d plus
daunorubicin 45mg/rn2 x 3d plus etoposide 100 mg/rn2 x 4d; AM = cytosine arabinoside
100 mg/rn2 x 7d plus mitoxantrone 12 mg/rn2 x 3d; HiD Ara-C = 1.5 gm/rn2 q12h x 3d; AC
= adriarnycin 60mg/rn2 plus cyclophosphamide 600 mg/rn2; FAC = 5-FU 500 mg/rn2 plus
adriamycin 50 mg/rn2 plus cyclophosphamide 500 mg/rn2; CMF = cyclophosphamide 600
mg/rn2 plus methotrexate 40 mg/rn2 plus 5-FU 600 mg/ m2; AN = adriamycin 50mg/rn2
plus nanelbine 30 mg/rn2, AT = adriamycin 50 mg/rn2 plus docetaxel 75mg/rn2; Paclitaxel
175 mg/rn2; NVB + CDDP = nanelbine 25 mg/rn2 day I & day 8 plus cisplatin 100 mg/rn2;
CHOP = cyclophospharnide 750 mg/rn2 plus adriamycin 50mg/rn2 plus vincristine 1.4 mg
plus prednisolone 60 mg; ABUD = adriamycin 25 mg/rn2 plus bleomycin 10 mg/rn2 plus
vinblastine 6 mg/rn2 plus DTIC 375 mg/rn2; COPP cyclophosphamide 650 mg/rn2 plus
vincristine 1.4 rng plus procarbazine 100 mg/rn2 x l4d plus prednisolone 40 mg ; Cyclo +
Carbo Platin = cyclophosphamide 750 mg/rn2 plus carboplatinum AUC5; Taxol + Carbo =
taxol 135 mg plus carboplatinum AUC 5; BEP = bleomycin 30 rng days 1, 8, and 15 plus
etoposide 100 mg/rn2 x 5d plus cisplatin 20 mg/rn2 x 5d; CDDP + 5FU cisplatin 100 mg/rn2
plus 5-FU 1 gm/m2 x 4 days; 1 fos + DOX = 1 fosfomide 3 gm/rn2 x 3d plus doxorubicin
20 mg/rn2 x 3 days; I fos + Etoposide = I fosfdmide 2 gm/rn2 x 3d plus etoposide 100
mg/rn2 x 3d; ICE 1 fosfomide 1.2 gm/rn2 x 5d plus carboplatinum 400 mg/rn2 plus
etoposide 100 mg/rn2 x 5d.
symptoms at time of presentation; duration of fever prior to study enrollment; days from
chemotherapy until admission; number of previous neutropenic episodes; duration of fever
and day of defervescence; absolute neutrophil count on day of defervescence; duration of
neutropenia; number and types of antibiotics used; day amphotericin B begun; number of
culture-documented infective episodes involving bloodstream, lung, pleura, urinary tract,
gastrointestinal tract, intravenous cannulae, or skin; types of antimicrobial isolates; cost of
cytokine therapy; length of hospital stay and clinical outcome.
Statistical Methods
Data were summarized as means with standard deviation, or medians with ranges (for
continuous variables) and as frequencies and percentages (for categorical variables).
Univariate analysis was performed using a two independent sample t-test, Pearson’s chisquare and Fisher’s exact test wherever appropriate. A p value < 0.05 was considered
statistically significant. Analyses were carried out using the statistics software program
SPSS (release 8.0.0, standard version, copyrightO SPSS Inc.).

Results

Demographic and clinical variables for the two study groups are shown in Table 2.

The groups were comparable in terms of numbers and percentages of hematologic and nonhematologic malignancies, days until fever, presenting symptoms, and absolute neutrophil
count at the time of fever. A significantly higher proportion of patients in the group
receiving growth factors had experienced previous episodes of febrile neutropenia.
Clinical outcomes
The absolute neutrophil count on the day of defervescence was higher in the growth factortreated group although the difference was not statistically significant (Table 3).

Requirements for antimicrobial agents were not significantly different (data not shown),
Patients treated with growth factors took more than one day longer to achieve
defervescence and also remained in the hospital one day longer (p < 0.008 and p < 0.018,

respectively). Six patients (9%) in the cytokine treatment group and 13 (16%) in the control
group died during febrile neutropenia (not statistically significant).
Sites of infection and recovery of pathogens
The numbers and types of clinically relevant infections and the recovery of pathogens from
blood, stool and several other body sites were comparable between the two groups.
However, more subjects in the cytokine-treated group had urinary tract infections (10
versus 4; p <0.05), while a significantly higher number of patients in the control group
were found to have pneumonia; overall, 15 patients developed radiographic evidence of
pulmonary infiltrates, 11 of cytokine therapy (p = 0.026). The incidences of pleural
effusions on chest x-ray were similar.
A total of 68 microbiologic isolates were cultured during 148 episodes of febrile
neutropenia (46% yield) (Table 4).

Overall the numbers of bacterial and fungal pathogens isolated from the two study groups
were comparable (Table 4). Aerobic Gram-negative bacteria were most commonly isolated
from both the treatment and control groups (22 versus 17 isolates, respectively); fewer
gram-positive bacteria were isolated from patients treated with growth factors (not
significant).
Discussion
Despite their widespread popularity in oncologic practice, there is a lack of published data
demonstrating clear survival benefits. Therfore the routine use of costly hematopoietic
colony stimulating factors as adjuvant therapy for neutropenic patients with unexplained

fever is not currently recommended9. The administration of G-CSF and GM-CSF in many
of the studies has demonstrated a reduction in the days to neutrophilic recoveiy and a
reduction of morbidity10-13. Rowe and associates used GM-CSF in older patients with acute
myeloid leukemia; the remission rate was 60% and 44% in the placebo group. Beneficial
effects including survival were also demonstrated in the GM-CSF arm. All these patients
had a day ten bone marrow performed and only if there were no leukemic cells in the
marrow was randomization done12.
In the present study of febrile patients recently undergoing induction chemotherapy, neither
GM-CSF nor G-CSF significantly reduced the duration of neutropenia or fever, decreased
the incidence of culture-proven infective episodes (except pneumonia), reduced the
duration of hospitalization, or improved overall clinical outcomes.
In an attempt to maximize patient benefits and minimize adverse effects on health care
systems and society, the American Society of Clinical Oncology (ASCO) and the
Infectious Diseases Society of America have published consensus guidelines for the
rational use of these agents with cancer chemotherapy and febrile neutropenia9,13. It should
be emphasized, however, that for many of these recommendations data from randomized
clinical trials are not available. The use of myeloid stimulating factors in cancer
chemotherapy induction is not routinely recommended but instead is based on risk
stratification of patients, itself being dependent on a number of clinical variables. For
certain conditions where worsening of the clinical course is predicted and there is an
expected long delay in recovery of the marrow, one of these agents may be indicated. Such
conditions include pneumonia, hypotensive episodes, severe cellulitis or sinusitis, systemic
fungal infections and multiorgan dysfunction secondary to sepsis. Therapy with colonystimulating factors may also be considered in patients who remain severely neutropenic and
have documented infections that fail to respond to appropriate antimicrobial treatment9,13.
There are several limitations of this study; firstly, data were collected retrospectively and
hence randomization was not possible. However, since the data were collected from
consecutive patients presenting over a short study period of 14 months, it minimized the
effects of several potential confounding variables. The short study period meant that
variations in certain variables (e.g., types of underlying cancers, chemotherapy doseintensities, patterns of microbial pathogen isolation and antibiotic resistance, use of
antifungal prophylaxis, and choices of empiric antimicrobial therapy) were notably limited.
Furthermore, the decision to use or not use growth factors (before and during the study)
was based purely on the basis of financial affordability by the patient, and thus may have
reduced potential bias in patient selectiOn. Another limitation of the study is that data for
G-CSF and GM-CSF were combined, although cytokine selection was made randomly.
Nevertheless, although some reports have suggested that G-CSF may result in a faster
neutrophil recovery compared to GM-CSF, this has not been a consistent finding and no
significant differences between the two agents have been reported for clinically-relevant
end points such as the infectious complications, length of hospitalization, use of antibiotics,
hospital costs and mortality.
Thirdly, treatment with growth factors was begun a mean of 11 and 13 days postchemotherapy in respective study groups and patients generally had experienced
neutropenia several days before the development of fever. This delayed initiation of
cytokine therapy was not because study subjects had low-risk (delayed-onset) neutropenia
but was due to the financial limitations of our patients. This practice is in line with ASCO

guidelines9.
In poorer countries like Pakistan very expensive therapeutics may adversely affect the
economics of the patient, family and society. In our setting the use of GMCSF and G-CSF
must be governed by proven efficacy, specific indications and cost-effectiveness. The
results of our study indicate that these cytokines may not confer significant benefits to
patients with uncomplicated febrile neutropenia and according to current guidelines should
be reserved for complicated cases where the expected risk of infection is high and the
duration of neutropenia is prolonged, or for patients with documented infections that are
refractory to antibiotic treatment.
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